S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
NASDAQ:MEDP

Medpace (MEDP) Stock Price, News & Analysis

$395.00
-7.30 (-1.81%)
(As of 04/12/2024 08:51 PM ET)
Today's Range
$392.71
$399.99
50-Day Range
$295.29
$413.31
52-Week Range
$185.43
$419.42
Volume
133,700 shs
Average Volume
241,648 shs
Market Capitalization
$12.24 billion
P/E Ratio
44.48
Dividend Yield
N/A
Price Target
$382.00

Medpace MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
3.3% Downside
$382.00 Price Target
Short Interest
Healthy
3.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
1.42mentions of Medpace in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$76.65 M Sold Last Quarter
Proj. Earnings Growth
20.89%
From $10.53 to $12.73 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.54 out of 5 stars

Medical Sector

90th out of 929 stocks

Commercial Physical Research Industry

3rd out of 11 stocks

MEDP stock logo

About Medpace Stock (NASDAQ:MEDP)

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

MEDP Stock Price History

MEDP Stock News Headlines

My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
Medpace (MEDP) to Release Quarterly Earnings on Monday
My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
Should You Invest in Medpace (MEDP)?
Insiders Are Selling These 5 Stocks in 2024
MEDP Apr 2024 580.000 call
Assessing Medpace Hldgs: Insights From 4 Financial Analysts
See More Headlines
Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/12/2024
Today
4/15/2024
Next Earnings (Confirmed)
4/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:MEDP
Employees
5,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$382.00
High Stock Price Target
$452.00
Low Stock Price Target
$273.00
Potential Upside/Downside
-3.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$282.81 million
Pretax Margin
17.80%

Debt

Sales & Book Value

Annual Sales
$1.89 billion
Cash Flow
$10.07 per share
Book Value
$18.22 per share

Miscellaneous

Free Float
23,020,000
Market Cap
$12.24 billion
Optionable
Optionable
Beta
1.38
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

MEDP Stock Analysis - Frequently Asked Questions

Should I buy or sell Medpace stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MEDP shares.
View MEDP analyst ratings
or view top-rated stocks.

What is Medpace's stock price target for 2024?

4 analysts have issued twelve-month target prices for Medpace's stock. Their MEDP share price targets range from $273.00 to $452.00. On average, they anticipate the company's share price to reach $382.00 in the next twelve months. This suggests that the stock has a possible downside of 3.3%.
View analysts price targets for MEDP
or view top-rated stocks among Wall Street analysts.

How have MEDP shares performed in 2024?

Medpace's stock was trading at $306.53 at the beginning of the year. Since then, MEDP stock has increased by 28.9% and is now trading at $395.00.
View the best growth stocks for 2024 here
.

When is Medpace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 22nd 2024.
View our MEDP earnings forecast
.

How can I listen to Medpace's earnings call?

Medpace will be holding an earnings conference call on Tuesday, April 23rd at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) released its quarterly earnings results on Monday, February, 12th. The company reported $2.46 earnings per share for the quarter, topping analysts' consensus estimates of $2.22 by $0.24. The firm had revenue of $498.40 million for the quarter, compared to analyst estimates of $498.72 million. Medpace had a net margin of 15.00% and a trailing twelve-month return on equity of 63.98%. Medpace's quarterly revenue was up 26.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.12 earnings per share.

What guidance has Medpace issued on next quarter's earnings?

Medpace updated its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided earnings per share (EPS) guidance of 10.180-10.870 for the period, compared to the consensus EPS estimate of 9.960. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

Medpace (MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Who are Medpace's major shareholders?

Medpace's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.85%), Congress Asset Management Co. MA (0.50%), Westwind Capital (0.14%), Annex Advisory Services LLC (0.13%), Rheos Capital Works Inc. (0.08%) and Bridge City Capital LLC (0.06%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Robert O Kraft, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends
.

How do I buy shares of Medpace?

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MEDP) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners